American Century Companies’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-141,828
| Closed | -$1.29M | – | 2870 |
|
|
2025
Q2 | $1.29M | Buy |
141,828
+20,859
| +17% | +$153K | ﹤0.01% | 2186 |
|
|
2025
Q1 | $962K | Buy |
120,969
+14,177
| +13% | +$104K | ﹤0.01% | 2260 |
|
|
2024
Q4 | $580K | Sell |
106,792
-225,820
| -68% | -$1.38M | ﹤0.01% | 2449 |
|
|
2024
Q3 | $2.4M | Buy |
332,612
+16,281
| +5% | +$149K | ﹤0.01% | 1891 |
|
|
2024
Q2 | $3.44M | Buy |
316,331
+48,041
| +18% | +$616K | ﹤0.01% | 1665 |
|
|
2024
Q1 | $5.03M | Buy |
268,290
+93,547
| +54% | +$2.16M | ﹤0.01% | 1448 |
|
|
2023
Q4 | $3.79M | Buy |
174,743
+7,073
| +4% | +$140K | ﹤0.01% | 1498 |
|
|
2023
Q3 | $3.45M | Sell |
167,670
-55,123
| -25% | -$1.59M | ﹤0.01% | 1477 |
|
|
2023
Q2 | $10.5M | Buy |
222,793
+14,231
| +7% | +$708K | 0.01% | 1036 |
|
|
2023
Q1 | $8.75M | Buy |
208,562
+2,209
| +1% | +$95K | 0.01% | 1065 |
|
|
2022
Q4 | $7.87M | Buy |
206,353
+2,155
| +1% | +$82.3K | 0.01% | 1058 |
|
|
2022
Q3 | $8M | Buy |
204,198
+21,772
| +12% | +$842K | 0.01% | 963 |
|
|
2022
Q2 | $5.89M | Sell |
182,426
-109,660
| -38% | -$3.68M | ﹤0.01% | 1073 |
|
|
2022
Q1 | $9.67M | Sell |
292,086
-30,830
| -10% | -$1.16M | 0.01% | 930 |
|
|
2021
Q4 | $13.7M | Buy |
322,916
+18,313
| +6% | +$767K | 0.01% | 796 |
|
|
2021
Q3 | $13.5M | Buy |
304,603
+15,033
| +5% | +$689K | 0.01% | 760 |
|
|
2021
Q2 | $16.4M | Sell |
289,570
-63,282
| -18% | -$4.47M | 0.01% | 709 |
|
|
2021
Q1 | $26.4M | Buy |
352,852
+144,693
| +70% | +$11.9M | 0.02% | 585 |
|
|
2020
Q4 | $18M | Sell |
208,159
-11,845
| -5% | -$873K | 0.01% | 640 |
|
|
2020
Q3 | $13.4M | Buy |
220,004
+239
| +0.1% | +$12.1K | 0.01% | 639 |
|
|
2020
Q2 | $9.14M | Buy |
219,765
+133
| +0.1% | +$4.83K | 0.01% | 696 |
|
|
2020
Q1 | $6.31M | Sell |
219,632
-654,850
| -75% | -$37.9M | 0.01% | 690 |
|
|
2019
Q4 | $63.1M | Buy |
874,482
+153,731
| +21% | +$18.9M | 0.06% | 317 |
|
|
2019
Q3 | $101M | Buy |
720,751
+205,435
| +40% | +$34.4M | 0.1% | 239 |
|
|
2019
Q2 | $94.3M | Sell |
515,316
-54,614
| -10% | -$9.32M | 0.09% | 257 |
|
|
2019
Q1 | $90.6M | Buy |
569,930
+39,835
| +8% | +$5.77M | 0.09% | 266 |
|
|
2018
Q4 | $50.8M | Buy |
530,095
+82,189
| +18% | +$9.41M | 0.06% | 335 |
|
|
2018
Q3 | $63.3M | Sell |
447,906
-79,156
| -15% | -$12.2M | 0.06% | 318 |
|
|
2018
Q2 | $82.5M | Buy |
527,062
+204,831
| +64% | +$32.2M | 0.08% | 287 |
|
|
2018
Q1 | $51.9M | Buy |
322,231
+292,995
| +1,002% | +$49.7M | 0.05% | 352 |
|
|
2017
Q4 | $4.82M | Buy |
29,236
+3,893
| +15% | +$377K | ﹤0.01% | 856 |
|
|
2017
Q3 | $1.58M | Buy |
25,343
+1,959
| +8% | +$154K | ﹤0.01% | 1074 |
|
|
2017
Q2 | $1.86M | Sell |
23,384
-3,387
| -13% | -$245K | ﹤0.01% | 1049 |
|
|
2017
Q1 | $1.9M | Sell |
26,771
-148
| -0.5% | -$8.67K | ﹤0.01% | 1048 |
|
|
2016
Q4 | $1.37M | Sell |
26,919
-5,134
| -16% | -$242K | ﹤0.01% | 1089 |
|
|
2016
Q3 | $1.48M | Buy |
+32,053
| New | +$1.3M | ﹤0.01% | 1107 |
|
Other funds holding SAGE
IA
HNB
American Century Companies's SAGE Position: Q3 2025 in Review
American Century Companies sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 141,828 shares — an estimated $1.29M sold.
American Century Companies first reported a position in SAGE in Q3 2016 and held it in 36 quarters. The position peaked at $101M in Q3 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- American Century Companies reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- American Century Companies sold 141,828 Sage Therapeutics shares in Q3 2025, an estimated $1.29M.
- American Century Companies first reported a position in Sage Therapeutics in Q3 2016 and held it in 36 quarters.
- American Century Companies's Sage Therapeutics position peaked at $101M in Q3 2019.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on American Century Companies's 13F filing for Q3 2025, filed 12 Nov 2025.